ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

4.58
0.00
(0.00%)
0.00
0.00
(0.00%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
4.58
Bid
4.40
Ask
4.70
Volume
-
0.00 Day's Range 0.00
3.8092 52 Week Range 6.63
Market Cap
Previous Close
4.58
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
569,387
Shares Outstanding
58,934,482
Dividend Yield
-
PE Ratio
-14.28
Earnings Per Share (EPS)
-0.32
Revenue
198.77M
Net Profit
-18.9M

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VNDA. The last closing price for Vanda Pharmaceuticals was $4.58. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of $ 3.8092 to $ 6.63.

Vanda Pharmaceuticals currently has 58,934,482 shares outstanding. The market capitalization of Vanda Pharmaceuticals is $269.92 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of -14.28.

VNDA Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-0.4347826086964.64.724.483137574.59149363CS
40.143.153153153154.444.84.173769884.44954043CS
12-0.24-4.979253112034.824.87033.80925693874.31363982CS
26-0.04-0.8658008658014.625.193.80925969624.50013608CS
52-1.72-27.30158730166.36.633.80926311264.88698153CS
156-4.93-51.8401682449.5111.93.2958531865.53167011CS
260-6.82-59.824561403511.421.86273.2957132678.01600062CS

VNDA - Frequently Asked Questions (FAQ)

What is the current Vanda Pharmaceuticals share price?
The current share price of Vanda Pharmaceuticals is $ 4.58
How many Vanda Pharmaceuticals shares are in issue?
Vanda Pharmaceuticals has 58,934,482 shares in issue
What is the market cap of Vanda Pharmaceuticals?
The market capitalisation of Vanda Pharmaceuticals is USD 269.92M
What is the 1 year trading range for Vanda Pharmaceuticals share price?
Vanda Pharmaceuticals has traded in the range of $ 3.8092 to $ 6.63 during the past year
What is the PE ratio of Vanda Pharmaceuticals?
The price to earnings ratio of Vanda Pharmaceuticals is -14.28
What is the cash to sales ratio of Vanda Pharmaceuticals?
The cash to sales ratio of Vanda Pharmaceuticals is 1.36
What is the reporting currency for Vanda Pharmaceuticals?
Vanda Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Vanda Pharmaceuticals?
The latest annual turnover of Vanda Pharmaceuticals is USD 198.77M
What is the latest annual profit for Vanda Pharmaceuticals?
The latest annual profit of Vanda Pharmaceuticals is USD -18.9M
What is the registered address of Vanda Pharmaceuticals?
The registered address for Vanda Pharmaceuticals is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Vanda Pharmaceuticals website address?
The website address for Vanda Pharmaceuticals is www.vandapharma.com
Which industry sector does Vanda Pharmaceuticals operate in?
Vanda Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.125
(0.00%)
0
AACGATA Creativity Global
$ 0.81
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.34
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.14
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.125
(0.00%)
0
AACGATA Creativity Global
$ 0.81
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.34
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.14
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.125
(0.00%)
0
AACGATA Creativity Global
$ 0.81
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.34
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.14
(0.00%)
0

VNDA Discussion

View Posts
eyeownu eyeownu 7 months ago
im a buyer at 5.07.nice triangle has formed. low float. plenty of cash on balance sheet. book value 9.20/sh
πŸ‘οΈ0
Zilla Zilla 8 months ago
WOW talk about being lucky. Bought calls Friday for 2025 just in case something happens in 2024. Up 20% pre-market with an 8 all cash offer on the table.
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
VNDA under $7
πŸ‘οΈ0
harry crumb harry crumb 11 months ago
Watching this closely
πŸ‘οΈ0
Monksdream Monksdream 11 months ago
VNDA under $10
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Over $6
πŸ‘οΈ0
tw0122 tw0122 1 year ago
Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Gonna be a winner. Patience
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Over 5$!
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
VNDA under $5
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Let er rip $$$$$$$$
πŸ‘οΈ0
Tiger Money Tiger Money 1 year ago
Agreed. This could double quickly
πŸ‘οΈ0
philaya philaya 1 year ago
got this today...
very good trades.
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
πŸ‘οΈ0
morokoy morokoy 1 year ago
Shares Outstanding 57,537,499 shares
Insider Shares 7,908,897 shares
Insider Ownership 13.75 %
Total Insiders 34
πŸ‘οΈ0
morokoy morokoy 1 year ago
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

Guess we'll have to wait on the promised 8K.

Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
πŸ‘οΈ0
harry crumb harry crumb 1 year ago
Minimum 8$ imo
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
REUTERS
1 mins ago
April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️ 1
MiamiGent MiamiGent 1 year ago
Probably...but I took it at 5.49
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Will it grow legs after 9:30
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA Vol picking up..

$5.49 +$1.44 (+35.56%)

Volume 3,354,569

90 DAV... 2M
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA Here we go
$5.3781 +$1.3281 (32.79%)

Bid ARCX
5.36 x 10
Ask XNMS
5.38 x 11
Volume
2,971,106
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA Vol is good. Already @ 90 DAV
Volume 2,056,421
10/90-day avg. volume
7M / 2M
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA Good post, Laster.
https://www.futurepak.com/
πŸ‘οΈ0
Laster Laster 1 year ago
The major question is who is Future Pak really?
Is this a legit offer?
Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
Large short position. Lots of selling PM at $5.
Market does not seem to believe this offer. Sorry.
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA Float 52.05M

Shares Short (3/28/2024) 2.49M
Short Ratio (3/28/2024) 2.78
Short % of Float (3/28/2024) 5.45%
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA
Bid EDGX
4.85 x 3
Ask EDGX
4.88 x 3

Volume
1,790,654
Avg Vol (10 day) 6.63M
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
Vanda Pharmaceuticals
Closed .01 (-0.25%)

Pre-market
$5.15 +1.10 (+27.16%)
As of Apr-17-2024 7:23:52 AM ET
Bid x size $5.14 x 1
Ask x size $5.16 x 3
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
VNDA In 5.12. Let's see, said the blind man.
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
πŸ‘οΈ0
MiamiGent MiamiGent 1 year ago
What's the news?
πŸ‘οΈ0
Awl416 Awl416 1 year ago
Damn
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Will it grow legs after 9:30
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
Will it grow legs after 9:30
πŸ‘οΈ0
tknuncle tknuncle 1 year ago
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
πŸ‘οΈ0
weedtrader420 weedtrader420 1 year ago
FDA Approve
πŸ‘οΈ0
Triple nickle Triple nickle 2 years ago
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 3 years ago
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the β€œComplaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 5 years ago
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
πŸ‘οΈ0
XenaLives XenaLives 5 years ago
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
πŸ‘οΈ0
Peepson Peepson 5 years ago
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
πŸ‘οΈ0
XenaLives XenaLives 5 years ago
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

πŸ‘οΈ0
otcmoneydoubler otcmoneydoubler 5 years ago
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
πŸ‘οΈ0
Peepson Peepson 5 years ago
Yo, does anyone still follow this board. I might have some interesting dd to share.
πŸ‘οΈ0
bezen bezen 8 years ago
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
πŸ‘οΈ0
Coz Mabluda Coz Mabluda 9 years ago
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



πŸ‘οΈ0
stocktrademan stocktrademan 9 years ago
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

πŸ‘οΈ0
ClearlyStocks ClearlyStocks 9 years ago
VNDA $16.74
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock